DOCSLIB.ORG

Revisions to USP 31–NF 26, Second Supplement

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Revisions to USP 31–NF 26, Second Supplement

(published May 2008)

Published April 2008

General Chapters Monographs:A–C D–N O–S T–Z

  • Monograph Title
  • Section Head
  • Scientific Liaison

DANTROLENE SODIUM CAPSULES PF 33(4) Pg. 645
Dissolution <711>
DEHYDROACETIC ACID PF 33(4) Pg. 703
Title
DEHYDROACETIC ACID PF 33(4) Pg. 703
Chemical Info
DEHYDROACETIC ACID PF 33(4) Pg. 703
Definition
DEHYDROACETIC ACID PF 33(4) Pg. 703
Packaging and storage USP Reference standards <11> Identification
DEHYDROACETIC ACID PF 33(4) Pg. 703

DEHYDROACETIC ACID PF 33(4) Pg. 703

DEHYDROACETIC ACID PF 33(4) Pg. 703
Heavy Metals, Method II <231> Loss on drying <731> Melting range, Class I <741> Residue on ignition <281> Assay
DEHYDROACETIC ACID PF 33(4) Pg. 703

DEHYDROACETIC ACID PF 33(4) Pg. 703

DEHYDROACETIC ACID PF 33(4) Pg. 703

DEHYDROACETIC ACID PF 33(4) Pg. 703

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Title 784

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Definition 784

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Packaging and storage 784

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Labeling 784

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. USP Reference stadards 784

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Identification 784

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Uniformity of dosage units 784

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Loss on drying 784

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Related compounds 784

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Assay 784

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 33(5) Pg. Title 903

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 33(5) Pg. Definition 903

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 33(5) Pg. Labeling 903

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 33(5) Pg. Loss on drying <731> 903

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 33(5) Pg. Acid-neutralizing capacity <301> 903

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 33(5) Pg. Related compounds 903

DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 33(5) Pg. Assay

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

903 DILTIAZEM HYDROCHLORIDE PF 33(5) Pg. 907
Definition
DIMENHYDRINATE INJECTION PF 33(5) Pg. 907
USP Reference standards <11> Identification
DIMENHYDRINATE INJECTION PF 33(5) Pg. 907

DIMENHYDRINATE PF 33(5) Pg. 907
Identification
DINOPROST TROMETHAMINE INJECTION PF 33(5) Pg. 908
Title
DINOPROST TROMETHAMINE INJECTION PF 33(5) Pg. 908
Definition
DINOPROST TROMETHAMINE INJECTION PF 33(5) Pg. 908
Packaging and storage Labeling
DINOPROST TROMETHAMINE INJECTION PF 33(5) Pg. 908

DINOPROST TROMETHAMINE INJECTION PF 33(5) Pg. 908
USP Reference standards <11> Identification
DINOPROST TROMETHAMINE INJECTION PF 33(5) Pg. 908

DINOPROST TROMETHAMINE INJECTION PF 33(5) Pg. 908
Bacterial endotoxins <85> Sterility <71> pH <791>
DINOPROST TROMETHAMINE INJECTION PF 33(5) Pg. 908

DINOPROST TROMETHAMINE INJECTION PF 33(5) Pg. 908

DINOPROST TROMETHAMINE INJECTION PF 33(5) Pg. 908
Other requirements Assay
DINOPROST TROMETHAMINE INJECTION PF 33(5) Pg. 908

ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761
Title
ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761
Definition
ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761
Packaging and storage Labeling
ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761

ENOXAPARIN SODIUM
USP Reference standards

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

INJECTION PF 31(3) Pg. 761 ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761
Identification A, B, C Clarity
ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761

ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761
Color
ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761 pH
ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761
Benzyl alcohol content Free sulfate content Anti-factor IIa activity Anti-factor Xa to anti-factor IIa ratio
ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761

ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761

ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761

ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761
Other requirements - Sterility Tests <71>

ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761
Other requirements Assay (anti-factor Xa activity) Bacterial endotoxins Definition
ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761

ENOXAPARIN SODIUM INJECTION PF 31(3) Pg. 761

ENOXAPARIN SODIUM INJECTION PF 33(1) Pg. 58

ENOXAPARIN SODIUM INJECTION PF 33(1) Pg. 58
Appearance of solution (Clarity and degree of color of liquids)

ENOXAPARIN SODIUM INJECTION PF 33(1) Pg. 58
Benzyl alcohol content (if present) Bacterial endotoxins <85> Free sulfate content
ENOXAPARIN SODIUM INJECTION PF 33(1) Pg. 58

ENOXAPARIN SODIUM INJECTION PF 33(1) Pg. 58

ENOXAPARIN SODIUM INJECTION PF 33(1) Pg. 58
Assay (anti-factor Xa activity) Title
ENOXAPARIN SODIUM PF 29(6) Pg. 1876

ENOXAPARIN SODIUM PF 29(6)
Chemical structure

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

Pg. 1876 ENOXAPARIN SODIUM PF 29(6) Pg. 1876
CAS number
ENOXAPARIN SODIUM PF 29(6) Pg. 1876
Definition
ENOXAPARIN SODIUM PF 29(6) Pg. 1876
Packaging and storage USP Reference standards Identification A, B, C, D, E Appearance of solution Specific absorbance pH
ENOXAPARIN SODIUM PF 29(6) Pg. 1876

ENOXAPARIN SODIUM PF 29(6) Pg. 1876

ENOXAPARIN SODIUM PF 29(6) Pg. 1876

ENOXAPARIN SODIUM PF 29(6) Pg. 1876

ENOXAPARIN SODIUM PF 29(6) Pg. 1876

ENOXAPARIN SODIUM PF 29(6) Pg. 1876
Loss on drying
ENOXAPARIN SODIUM PF 29(6) Pg. 1876
Nitrogen content
ENOXAPARIN SODIUM PF 29(6) Pg. 1876
Heavy metals
ENOXAPARIN SODIUM PF 29(6) Pg. 1876
Sodium content
ENOXAPARIN SODIUM PF 29(6) Pg. 1876
Molar ratio of sulfate to carboxylate Benzyl alcohol content Anti-factor IIa activity Assay (anti-factor Xa activity) Bacterial endotoxins Definition
ENOXAPARIN SODIUM PF 29(6) Pg. 1876

ENOXAPARIN SODIUM PF 29(6) Pg. 1876

ENOXAPARIN SODIUM PF 29(6) Pg. 1876

ENOXAPARIN SODIUM PF 29(6) Pg. 1876

ENOXAPARIN SODIUM PF 33(1) Pg. 52

ENOXAPARIN SODIUM PF 33(1) Pg. 52
USP Reference standards <11> Identification
ENOXAPARIN SODIUM PF 33(1)

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

Pg. 52 ENOXAPARIN SODIUM PF 33(1) Appearance of solution (Clarity and

  • Pg. 52
  • degree of color of liquids)

ENOXAPARIN SODIUM PF 33(1) Pg. 52 pH <791>
ENOXAPARIN SODIUM PF 33(1) Molar ratio of sulfate to carboxylate

  • Pg. 52
  • (see Chromatography <621>)

ENOXAPARIN SODIUM PF 33(1) Pg. 52
Benzyl alcohol content
ENOXAPARIN SODIUM PF 33(1) Pg. 52
Anti-factor IIa activity
ENOXAPARIN SODIUM PF 33(1) Pg. 52
Assay (anti-factor Xa activity)
ESTRADIOL AND NORETHINDRONE ACETATE TABLETS PF 31(5) Pg. 1364
Dissolution Dissolution
ESTRADIOL AND NORETHINDRONE ACETATE TABLETS PF 33(2) Pg. 220

ETHINYL ESTRADIOL TABLETS PF 31(4) Pg. 1067
Disintegration

  • Assay
  • ETHIONAMIDE PF 33(4) Pg. 648

FAMOTIDINE TABLETS PF 33(4) Pg. 649
Dissolution <711>
FORMALDEHYDE SOLUTION PF 33(4) Pg. 650
Definition
FORMALDEHYDE SOLUTION PF 33(4) Pg. 650
Labeling
FORMALDEHYDE SOLUTION PF 33(4) Pg. 650
Content of methanol Assay
FORMALDEHYDE SOLUTION PF 33(4) Pg. 650

FULVESTRANT PF 33(5) Pg. 909 FULVESTRANT PF 33(5) Pg. 909 FULVESTRANT PF 33(5) Pg. 909 FULVESTRANT PF 33(5) Pg. 909 FULVESTRANT PF 33(5) Pg. 909 FULVESTRANT PF 33(5) Pg. 909 FULVESTRANT PF 33(5) Pg. 909
Title Chemical Info Definition Packaging and storage USP Reference standards <11> Identification Specific rotation <781S>

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

FULVESTRANT PF 33(5) Pg. 909 FULVESTRANT PF 33(5) Pg. 909 FULVESTRANT PF 33(5) Pg. 909 FULVESTRANT PF 33(5) Pg. 909 FULVESTRANT PF 33(5) Pg. 909
Water, Method Ic <921> Residue on ignition <281> Related compounds Diastereoisomer ratio Assay
GAMMA CYCLODEXTRIN PF 31(3) Pg. 812
Microbial limits Title
GAMMA CYCLODEXTRIN PF 31(3) Pg. 812

GAMMA CYCLODEXTRIN PF 31(3) Pg. 812
Molecular weight Packaging and storage Identification A, B, C Specific rotation Loss on drying
GAMMA CYCLODEXTRIN PF 31(3) Pg. 812

GAMMA CYCLODEXTRIN PF 31(3) Pg. 812

GAMMA CYCLODEXTRIN PF 31(3) Pg. 812

GAMMA CYCLODEXTRIN PF 31(3) Pg. 812

GAMMA CYCLODEXTRIN PF 31(3) Pg. 812
Residue on ignition Heavy metals
GAMMA CYCLODEXTRIN PF 31(3) Pg. 812

GAMMA CYCLODEXTRIN PF 33(4) Pg. 707
Chemical Info
GAMMA CYCLODEXTRIN PF 33(4) Pg. 707
Definition
GAMMA CYCLODEXTRIN PF 33(4) Pg. 707
USP Reference standards <11> Color and clarity of solution Related compounds Reducing substances Assay
GAMMA CYCLODEXTRIN PF 33(4) Pg. 707

GAMMA CYCLODEXTRIN PF 33(4) Pg. 707

GAMMA CYCLODEXTRIN PF 33(4) Pg. 707

GAMMA CYCLODEXTRIN PF 33(4) Pg. 707

GLUCOSAMINE

  • HYDROCHLORIDE PF 33(4) Pg.
  • Specific rotation <781S>

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

691 GLUCOSAMINE SULFATE POTASSIUM CHLORIDE PF 33(4) Identification Pg. 692

GLUCOSAMINE SULFATE POTASSIUM CHLORIDE PF 33(4) Specific rotation <781S> Pg. 692

GLUCOSAMINE SULFATE POTASSIUM CHLORIDE PF 33(4) Residue on ignition <281> Pg. 692

GLUCOSAMINE SULFATE SODIUM CHLORIDE PF 33(4) Pg. Identification 692

GLUCOSAMINE SULFATE SODIUM CHLORIDE PF 33(4) Pg. Specific rotation <781S> 692

GLUCOSAMINE SULFATE SODIUM CHLORIDE PF 33(4) Pg. Residue on ignition <281> 692

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS PF
Labeling
33(4) Pg. 654 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS PF
Dissolution <711>
33(4) Pg. 654 HYDROPHOBIC COLLOIDAL
Title
SILICA PF 33(5) Pg. 976

HYDROPHOBIC COLLOIDAL
Chemical Info
SILICA PF 33(5) Pg. 976

HYDROPHOBIC COLLOIDAL
Definition
SILICA PF 33(5) Pg. 976

HYDROPHOBIC COLLOIDAL
Packaging and storage
SILICA PF 33(5) Pg. 976

HYDROPHOBIC COLLOIDAL
Identification
SILICA PF 33(5) Pg. 976

HYDROPHOBIC COLLOIDAL
Limit of chloride
SILICA PF 33(5) Pg. 976

HYDROPHOBIC COLLOIDAL
Limit of lead
SILICA PF 33(5) Pg. 976

HYDROPHOBIC COLLOIDAL
Water-dispersible substances
SILICA PF 33(5) Pg. 976

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

HYDROPHOBIC COLLOIDAL SILICA PF 33(5) Pg. 976
Loss on ignition <733> Assay
HYDROPHOBIC COLLOIDAL SILICA PF 33(5) Pg. 976

HYOSCYAMINE SULFATE PF 33(4) Pg. 659
Specific rotation <781S>
INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 INOSITOL PF 33(4) Pg. 711 ISOSORBIDE MONONITRATE
Title Chemical Info Definition Packaging and storage USP Reference standards <11> Clarity of solution Color of solution Identification Conductivity Water, Method I <921> Barium Limit of lead Related compounds Assay

EXTENDED-RELEASE TABLETS Dissolution <711> PF 33(4) Pg. 659

ISOTRETINOIN CAPSULES PF
Dissolution <711>
33(4) Pg. 666

IVERMECTIN AND CLORSULON
Title
INJECTION PF 33(5) Pg. 921

IVERMECTIN AND CLORSULON
Definition
INJECTION PF 33(5) Pg. 921

IVERMECTIN AND CLORSULON
Packaging and storage
INJECTION PF 33(5) Pg. 921

IVERMECTIN AND CLORSULON
Labeling
INJECTION PF 33(5) Pg. 921

IVERMECTIN AND CLORSULON INJECTION PF 33(5) Pg. 921
USP Reference standards <11> Identification
IVERMECTIN AND CLORSULON INJECTION PF 33(5) Pg. 921

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

IVERMECTIN AND CLORSULON INJECTION PF 33(5) Pg. 921
Bacterial endotoxins <85> Sterility <71>
IVERMECTIN AND CLORSULON INJECTION PF 33(5) Pg. 921

IVERMECTIN AND CLORSULON INJECTION PF 33(5) Pg. 921
Other requirements Assay for ivermectin Assay for clorsulon Title
IVERMECTIN AND CLORSULON INJECTION PF 33(5) Pg. 921

IVERMECTIN AND CLORSULON INJECTION PF 33(5) Pg. 921

IVERMECTIN INJECTION PF 33(5) Pg. 913

IVERMECTIN INJECTION PF 33(5) Pg. 913
Definition
IVERMECTIN INJECTION PF 33(5) Pg. 913
Packaging and storage Labeling
IVERMECTIN INJECTION PF 33(5) Pg. 913

IVERMECTIN INJECTION PF 33(5) Pg. 913
USP Reference standards <11> Identification
IVERMECTIN INJECTION PF 33(5) Pg. 913

IVERMECTIN INJECTION PF 33(5) Pg. 913
Bacterial endotoxins <85> Sterility <71>
IVERMECTIN INJECTION PF 33(5) Pg. 913

IVERMECTIN INJECTION PF 33(5) Pg. 913
Chromatographic purity Other requirements Assay
IVERMECTIN INJECTION PF 33(5) Pg. 913

IVERMECTIN INJECTION PF 33(5) Pg. 913

IVERMECTIN PASTE PF 33(5) Pg. 914
Title
IVERMECTIN PASTE PF 33(5) Pg. 914
Definition
IVERMECTIN PASTE PF 33(5) Pg. 914
Packaging and storage Labeling
IVERMECTIN PASTE PF 33(5) Pg. 914

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

IVERMECTIN PASTE PF 33(5) Pg. 914
USP Reference standards <11> Identification
IVERMECTIN PASTE PF 33(5) Pg. 914

IVERMECTIN PASTE PF 33(5) Pg. 914
Chromatographic purity
IVERMECTIN PASTE PF 33(5) Pg. 914
Assay

  • IVERMECTIN PF 33(5) Pg. 912
  • Definition

Title
IVERMECTIN TABLETS PF 33(5) Pg. 918

IVERMECTIN TABLETS PF 33(5) Pg. 918
Definition
IVERMECTIN TABLETS PF 33(5) Pg. 918
Packaging and storage USP Reference standards <11> Identification
IVERMECTIN TABLETS PF 33(5) Pg. 918

IVERMECTIN TABLETS PF 33(5) Pg. 918

IVERMECTIN TABLETS PF 33(5) Pg. 918
Uniformity of dosage units <905> Limit of 8a-oxo-H2B1a Assay
IVERMECTIN TABLETS PF 33(5) Pg. 918

IVERMECTIN TABLETS PF 33(5) Pg. 918

IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg. 916
Title
IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg. 916
Definition
IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg. 916
Packaging and storage Labeling
IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg. 916

IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg. 916
USP Reference standards <11> Identification
IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg. 916

IVERMECTIN TOPICAL SOLUTION PF 33(5) Pg. 916
Chromatographic purity Assay
IVERMECTIN TOPICAL

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

SOLUTION PF 33(5) Pg. 916 LIGHT MINERAL OIL PF 33(5) Pg. 972
Definition
LIGHT MINERAL OIL PF 33(5) Pg. 972
Packaging and storage Labeling
LIGHT MINERAL OIL PF 33(5) Pg. 972

LIGHT MINERAL OIL PF 33(5) Pg. 972
USP Reference standards <11> Identification
LIGHT MINERAL OIL PF 33(5) Pg. 972

LIGHT MINERAL OIL PF 33(5) Pg. 972
Viscosity <911> Acidity,Readily carbonizable
LIGHT MINERAL OIL PF 33(5) Pg. substances, Limit of polycyclic

  • 972
  • aromatic hydrocarbons, Limit of

sulfur compounds, and Solid paraffin

MAGALDRATE AND SIMETHICONE ORAL SUSPENSION PF 33(5) Pg. 923
Defoaming activity Defoaming activity Defoaming activity Assay
MAGALDRATE AND SIMETHICONE TABLETS PF 33(5) Pg. 923

MAGALDRATE AND SIMETHICONE TABLETS PF 33(5) Pg. 923

MEFLOQUINE HYDROCHLORIDE PF 33(4) Pg. 667

MINERAL OIL PF 33(5) Pg. 962 MINERAL OIL PF 33(5) Pg. 962 MINERAL OIL PF 33(5) Pg. 962 MINERAL OIL PF 33(5) Pg. 962 MINERAL OIL PF 33(5) Pg. 962 MINERAL OIL PF 33(5) Pg. 962 MINERAL OIL PF 33(5) Pg. 962 MINERAL OIL PF 33(5) Pg. 962 MINERAL OIL PF 33(5) Pg. 962
Chemical Info Definition Packaging and storage Labeling USP Reference standards <11> Identification Neutrality Acidity Readily carbonizable substances Limit of polycyclic aromatic hydrocarbons
MINERAL OIL PF 33(5) Pg. 962

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

MINERAL OIL PF 33(5) Pg. 962 MINERAL OIL PF 33(5) Pg. 962
Limit of sulfur compounds Viscosity
MINERAL OIL, RECTAL PF 33(5) Pg. 964
Packaging and storage USP Reference standards <11> Identification
MINERAL OIL, RECTAL PF 33(5) Pg. 964

MINERAL OIL, RECTAL PF 33(5) Pg. 964

MINERAL OIL, RECTAL PF 33(5) Pg. 964
Viscosity
MINERAL OIL, RECTAL PF 33(5) Pg. 964
Neutrality
MINERAL OIL, RECTAL PF 33(5) Pg. 964
Acidity
MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924
Title
MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924
Chemical Info
MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924
Definition
MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924
Packaging and storage USP Reference standards <11> Identification
MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924

MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924

MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924
Melting range, Class Ia <741> Loss on drying <731> Residue on ignition <281> Heavy metals, Method II <231> Related compounds Assay
MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924

MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924

MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924

MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924

MYCOPHENOLATE MOFETIL PF 33(5) Pg. 924

NAPHAZOLINE HYDROCHLORIDE

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

Assay
OPHTHALMIC SOLUTION PF

33(5) Pg. 926

NICOTINE TRANSDERMAL SYSTEM PF 33(5) Pg. 927
Drug release <724> Assay
NICOTINE TRANSDERMAL SYSTEM PF 33(5) Pg. 927

NORETHINDRONE TABLETS PF 32(6) Pg. 1736
Labeling
NORETHINDRONE TABLETS PF 32(6) Pg. 1736
Disintegration <701> Dissolution <711>
NORETHINDRONE TABLETS PF 33(3) Pg. 432

General Chapters Monographs:A–C D–N O–S T–Z

file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM]

Recommended publications
  • Inositol Safety: Clinical Evidences

    Inositol Safety: Clinical Evidences

    European Review for Medical and Pharmacological Sciences 2011; 15: 931-936 Inositol safety: clinical evidences G. CARLOMAGNO, V. UNFER AGUNCO Obstetrics & Gynecology Center, Rome (Italy) Abstract. – Myo-inositol is a six carbon ent required by the human cells for the growth cyclitol that contains five equatorial and one axi- and survival in the culture. In humans and other al hydroxyl groups. Myo-inositol has been classi- species, Myo-inositol can be converted to either fied as an insulin sensitizing agent and it is L- or D-chiro-inositol by epimerases. Early stud- commonly used in the treatment of the Polycys- tic Ovary Syndrome (PCOS). However, despite ies showed that inositol urinary clearance was al- its wide clinical use, there is still scarce informa- tered in type 2 diabetes patients, the next step tion on the myo-inositol safety and/or side ef- was to link impaired inositol clearance with in- fects. The aim of the present review was to sum- sulin resistance (for a review see1). Because of marize and discuss available data on the myo-in- these properties, inositol have been classified as ositol safety both in non-clinical and clinical set- “insulin sensitizing agent”2. tings. The main outcome was that only the highest In the recent years, inositol has found more dose of myo-inositol (12 g/day) induced mild and more space in the reproductive clinical prac- gastrointestinal side effects such as nausea, fla- tice3-6. Indeed, since the main therapy for Poly- tus and diarrhea. The severity of side effects did cystic Ovary Syndrome (PCOS) is the use of in- not increase with the dosage.
  • Genetic Control of Apigenin Di-C-Glycoside Biosynthesis in Bread Wheat Grain and Their Role

    Genetic Control of Apigenin Di-C-Glycoside Biosynthesis in Bread Wheat Grain and Their Role

    Genetic control of Apigenin di-C-glycoside biosynthesis in bread wheat grain and their role as yellow pigments of Asian alkaline noodles Submitted by Grace Yasmein Wijaya This thesis is submitted to Faculty of Sciences in fulfilment of the requirements for the degree Doctor of Philosophy Faculty of Science The University of Adelaide November 2012 This book is An Answer to Prayers of a Long list of Believers I have been very blessed and loved with all of your spiritual supports, for His guidance and protections, and sincerely will not have enough to thank you all..... May you all be blessed and loved, too As I have been always, yasmein Table of Content Table of Content i List of Tables x List of Figures xiii List of Supplemental Materials xxv Summary xxx Statement of Authorship xxxiv List of Publications xxxv Acknowledgement xxxvi List of Abbreviations xxxix Chapter I: General Introduction 1 1.1 Background 1 1.2 Knowledge Gap 2 1.3 Structure of thesis 2 Chapter II: Literature review 4 2.1 Asian noodles as one of the major end-products of Australian bread wheat 4 2.2 Yellow colour of YAN 5 2.2.1 Natural Compounds that contribute to the yellow colour of YAN 5 2.2.1.1 Types of natural compounds that contributes to the yellow colour of YAN and their roles in plants and human health 5 2.2.1.2 Contribution of xanthophylls and ACGs to the yellow colour of alkaline noodles 8 2.2.2 Factors influencing the measurement of the yellowness of noodles and the content of xanthophyll and ACG in wheat grain 10 i 2.2.3 The amount, tissue location and composition
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Inositol (Powder) Introduced 2008

    Inositol (Powder) Introduced 2008

    Product Information Sheet – March 2016 Inositol (powder) Introduced 2008 What Is It? Inositol (powder) Inositol is a component of the B-complex family. It supports healthy two scoops (approximately 4.2 g) contain v central nervous system function, including emotional wellness, healthy mood and behavior. Additionally, it may promote ovarian health.* inositol (as myo-inositol) .................................................................................4.2 g serving size: approximately 4.2 g (2 scoops) Uses For Inositol (powder) servings per container: 60 Emotional Wellness: Myo-inositol is the primary form of inositol 2 scoops, 1–2 times daily, with or between meals, or as directed found in the central nervous system. It plays an important role in cell by a health professional. membrane formation and serves as part of the phosphatidylinositol second messenger system, supporting serotonin, norepinenephrine and cholinergic receptor function. As a result, inositol may support healthy mood, emotional wellness and behavior, and ease occasional nervous tension.* Ovarian Function: Research suggests that myo-inositol may help to support healthy ovulatory activity, ovarian function and reproductive system function.* What Is The Source? Myo-inositol is derived from rice bran. Recommendations Pure Encapsulations® recommends 2 scoops, 1–2 times daily, with or between meals, or as directed by a health professional. Are There Any Potential Side Effects Or Precautions? Rarely, inositol has been associated with nausea, fatigue, headache or dizziness. If pregnant or lactating, consult your physician before taking this product. Are There Any Potential Drug Interactions? At this time, there are no known adverse reactions when taken in conjunction with medications. Consult your physician for more information. *These statements have not been evaluated by the Food and Drug Administration.
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T

    WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
  • Synthesis of Mannosylglucosaminylinositol

    Synthesis of Mannosylglucosaminylinositol

    Proc. Nati. Acad. Sci. USA Vol. 89, pp. 6025-6029, July 1992 Medical Sciences Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal hemoglobinuria cells (complement/decay-accelerating factor/CD59) SHINICHI HIROSE*, LAKSHMESWARI RAVI*, GREGORY M. PRINCE*, MELVIN G. ROSENFELDt, ROBERT SILBERf, STEVEN W. ANDRESEN§, SANDRA V. HAZRA¶, AND M. EDWARD MEDOF*II *Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106; Departments of tCell Biology and *Medicine, New York University Medical Center, New York, NY 10016; §Cleveland Clinic Foundation, Cleveland, OH 44106; and lAkron General Medical Center, Akron, OH 44307 Communicated by Frederick C. Robbins, November 29, 1991 (received for review September 12, 1991) ABSTRACT To identify mannosyl (Man)-containing inter- have been identified, information concerning the biochemical mediates ofthe human glycoinositol phospholipid (GPI) anchor pathway(s) responsible for their intracellular GPI-anchor pathway and examine their expression in paroxysmal nocturnal assembly and protein incorporation is only beginning to hemoglobinuria (PNH), mannolipid products deriving from in emerge. vitro guanosine diphosphate [3HJMan labeling of HeLa cell Among human GPI-anchored proteins are the decay- microsomes were characterized. The defined GPI species were accelerating factor (DAF) and CD59, membrane-associated correlated with products deriving from in vivo [3HJMan label- regulators of the complement cascade which protect host ing of normal and (GPI-anchor defective) affected leukocytes. tissues from autologous complement attack (reviewed in refs. In vitro analyses in HeLa cells showed dolichol-phosphoryl 2-4). Deficient expression of these proteins underlies an (Dol-P)-[3H]Man and a spectrum of [3H]Man lipids exhibiting acquired hemolytic disorder termed paroxysmal nocturnal TLC mobilities approximating those of Trypanosoma brucei hemoglobinuria (PNH), and the lesion responsible for the (Tryp) GPI precursors.
  • Ion Channels

    Ion Channels

    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
  • Inhibition of Vessel Permeability by TNP-470 and Its Polymer Conjugate, Caplostatin

    Inhibition of Vessel Permeability by TNP-470 and Its Polymer Conjugate, Caplostatin

    ARTICLE Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin Ronit Satchi-Fainaro,1 Roni Mamluk,1 Ling Wang,3 Sarah M. Short,1 Janice A. Nagy,2 Dian Feng,2 Ann M. Dvorak,2 Harold F. Dvorak,2 Mark Puder,1 Debabrata Mukhopadhyay,2,3 and Judah Folkman1,* 1Children’s Hospital Boston and Harvard Medical School, Vascular Biology Program, Department of Surgery, 1 Blackfan Circle, Karp Family Research Laboratories, Floor 12, Boston, Massachusetts 02115 2 Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215 3 Biochemistry and Molecular Biology and Mayo Cancer Center, Mayo Clinic, Rochester, Minnesota 55905 *Correspondence: [email protected] Summary Angiogenesis inhibitors, such as TNP-470 and the nontoxic HPMA copolymer-TNP-470 (caplostatin), are emerging as a class of anticancer drugs. We report that TNP-470 and caplostatin inhibit vascular hyperpermeability of tumor blood vessels as well as that induced in mouse skin by different mediators. Treatment with TNP-470 or angiostatin for 3 days was sufficient to reduce permeability of tumor blood vessels, delayed-type hypersensitivity, and pulmonary edema induced by IL-2. TNP-470 also inhibited VPF/VEGF-induced phosphorylation of VEGFR-2, calcium influx, and RhoA activation in endothelial cells. These results identify an activity of TNP-470, that of inhibiting vessel hyperpermeability. This activity likely contributes to TNP-470’s antiangiogenic effect and suggests that caplostatin can be used in the treatment of cancer and inflammation. Introduction vival, and permeability) by activating VEGFR-2 (Claesson- Welsh, 2003). Angiogenesis, the generation of new blood vessels from preex- While EC proliferation is an important component of angio- isting microvasculature (Folkman and Kalluri, 2003), is regu- genesis (Koch et al., 1994), VPF/VEGF has relatively weak mi- lated by a number of different growth factors (Matsumoto and togenic activity compared to other factors such as basic fibro- Claesson-Welsh, 2001).
  • WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T

    WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61K 31/5517 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61P 31/22 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/551 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/NL20 14/050781 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 November 2014 (13.1 1.2014) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/903,433 13 November 2013 (13.
  • Targeting HDAC Complexes in Asthma and COPD

    Targeting HDAC Complexes in Asthma and COPD

    epigenomes Review Targeting HDAC Complexes in Asthma and COPD Martijn R. H. Zwinderman, Sander de Weerd and Frank J. Dekker * Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, 9713 AV Groningen, The Netherlands * Correspondence: [email protected]; Tel.: +31-50-363-8030 Received: 28 June 2019; Accepted: 4 September 2019; Published: 7 September 2019 Abstract: Around three million patients die due to airway inflammatory diseases each year. The most notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD). Therefore, new therapies are urgently needed. Promising targets are histone deacetylases (HDACs), since they regulate posttranslational protein acetylation. Over a thousand proteins are reversibly acetylated, and acetylation critically influences aberrant intracellular signaling pathways in asthma and COPD. The diverse set of selective and non-selective HDAC inhibitors used in pre-clinical models of airway inflammation show promising results, but several challenges still need to be overcome. One such challenge is the design of HDAC inhibitors with unique selectivity profiles, such as selectivity towards specific HDAC complexes. Novel strategies to disrupt HDAC complexes should be developed to validate HDACs further as targets for new anti-inflammatory pulmonary treatments. Keywords: asthma; COPD; inflammation; NF-κB; HDAC; acetylation; post translational modification (PTM); inhibitor; drug design; co-repressor complex; review 1. Introduction Inflammatory pulmonary diseases are among the most common health problems worldwide. Currently, approximately 339 million people suffer from asthma, which results in 250 thousand preventable deaths annually [1,2]. Similar numbers have been reported for Chronic Obstructive Pulmonary Disease (COPD). About 384 million people were estimated to have COPD and 3 million people died because of it in 2010 [3–6].
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
  • Astrocyte Function in Alcohol Reward and Addiction

    Astrocyte Function in Alcohol Reward and Addiction

    lism and D ho ru o g lc D A e p f e o Journal of n l Adermark, J Alcohol Drug Depend 2015, 3:4 d a e n r n c u e o DOI; 10.4172/2329-6488.1000e123 J ISSN: 2329-6488 Alcoholism & Drug Dependence EditorialResearch Article OpenOpen Access Access Astrocyte Function in Alcohol Reward and Addiction Louise Adermark* Addiction Biology Unit, Sahlgrenska Academy, Institute of Neuroscience and Physiology, University of Gothenburg, Box 410, SE-405 30 Gothenburg, Sweden Abstract Glial cells, particularly astrocytes, play essential roles in the regulation of neurotransmission, metabolism, and supply of energy substrates for synaptic transmission. One astrocyte can receive inputs from several hundreds of synapses, and synchronized neuronal activity correlates with astrocyte calcium signaling. Astrocyte pathology is a common feature of ethanol exposure in both humans and animal models, and brief alcohol intake is sufficient to cause long-lasting changes in astrocyte gene expression, activity and proliferation. Recent research also suggests that astrocytes shape the rewarding sensation of ethanol, and might be involved in modulating alcohol consumption. Considering the role of astrocytes in regulating glutamate homeostasis, a crucial component of alcohol abuse disorders, the astrocyte might be an important target for the development of new pharmacological treatments of alcoholism. Keywords: Alcohol; Astrocytes; Astroglia; Glia; GFAP; Dopamine; dependent glutamate-glutamine cycle is required to maintain active Ethanol neurotransmission at excitatory terminals, but may also play a vital role for GABAergic neurotransmission [20,21]. Inhibitory transmission is Astrocytes further regulated by astrocytes through glycine transporters GlyT1 The astroglial cell, or astrocyte, is the most numerous cell type of and GlyT2, and GABA transporters GAT-1 and GAT-3 [22,23], the glial cell family.